A committee of American experts unanimously agreed to recommend the administration of a second dose of Johnson & Johnson vaccine for Covid-19.
This proposal may allay the concerns of the 15 million Americans who had been vaccinated against the monotonous vaccine but wondered if it was enough to protect them, especially after the Delta variant spread.
The committee members, who met at the request of the US Food and Drug Administration (FDA), agreed that the evidence on the safety and efficacy of the vaccine was sufficient to recommend a second dose, as argued by the pharmaceutical industry.
However, this recommendation may be amended by the FDA or the CDC, the federal Centers for Disease Control and Prevention. Urgent approval of these services may be given in the coming days or weeks.
Some of these independent experts have suggested that although J&J requested that a "booster dose" be approved, this dose should be considered "supplementary" in order to achieve a more complete vaccination. "I sincerely believe that this has always been a two-dose vaccine. "It's complicated to recommend it as a single dose," said Paul Ofit, an immunization specialist at Philadelphia Pediatric Hospital.
In its US study, J&J reported that the effectiveness of its vaccine against the symptomatic form of Covid-19 increased from 70% to 94% after a second dose two months after the first dose, rates that are similar to those of vaccines using messenger RNA technology (Pfizer, Moderna).
Yesterday, the committee recommended giving a booster dose of the Moderna vaccine to vulnerable people, especially those over 65 and those who, due to the nature of their work, are more at risk of being exposed to the virus. A similar decision was made several weeks ago for the Pfizer vaccine.
The J&J vaccine proposal applies to all people over the age of 18 who took the first dose at least two months ago.